Navigation Links
Pharmasset Accesses up to $30 Million of Working Capital
Date:10/4/2007

PRINCETON, N.J., Oct. 4 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) has entered into a working capital loan agreement with Horizon Technology Finance LLC. Subject to certain terms and conditions of the agreement, Horizon will advance $10 million to Pharmasset in the near future. At its option, Pharmasset may receive a second loan of $10 million by March 31, 2008 and a third loan of $10 million by November 30, 2008, provided conditions precedent to making the additional loans are satisfied. Horizon has committed to $20 million of the loan facility, and Horizon intends to syndicate the remaining $10 million.

"When combined with our existing cash position, this financing is expected to fully fund the clevudine Phase 3 registration studies through the New Drug Application filing with the FDA," stated Kurt Leutzinger, Pharmasset's Executive Vice President & Chief Financial Officer. "In light of the recent and anticipated progress of our clinical development programs, we believe this facility also supports our goal of minimizing equity dilution for our stockholders by providing flexibility regarding the timing of any future equity financings."

For each $10 million loan, Pharmasset will pay interest only for the first 15 months followed by 30 equal monthly installments of principal and accrued interest. The interest rate for the initial loan will be 12%. In addition, Pharmasset issued to Horizon a seven-year warrant to purchase up to 149,377 shares of common stock at an exercise price of $12.05 per share, a volume- weighted average of recent closing prices. The warrant is immediately exercisable for 66,390 shares, and the remaining 82,987 shares become exercisable in varying increments upon the achi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venture Investors early-stage fund grows to $115 million
2. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
3. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
4. TomoTherapy raises $223 million in IPO
5. Fiserv reports $113.5 million in Q1 profit
6. Investors raise $25 million for biodiesel plant
7. Grow Milwaukee includes millions for tech funding
8. Mirus Bio, Pfizer enter multimillion-dollar research agreement
9. ConjuGon raises $3.3 million to fund clinical trials
10. TrafficCast secures $1 million line of credit
11. Make Mine a $Million shoots for May program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... periods ended September 30, 2014.  Biorem,s complete 2014 third quarter financial ... Financial Summary:Three-months ended September 30, , Nine-months ... data) , 2014 , 2013 , ... , 5,281 , 6,715 , 14,476 ...
(Date:11/18/2014)... FL (PRWEB) November 17, 2014 ... point-of-care diagnostic tests – today announces its third ... and Prevention’s (CDC) Get Smart About Antibiotics Week ... Week is a national campaign designed to highlight ... health departments, and non-profit and for-profit partners to ...
(Date:11/18/2014)... 17, 2014 pH measurement and control ... the pharmaceutical, chemical, and food and beverage industries. But ... and how do pH sensors work? METTLER TOLEDO has ... in process industries with these questions and more. , ... in the process industries. The actual sensor, the pH ...
(Date:11/18/2014)... 18, 2014 Alanda Software, a ... Reporting solutions, announced today that a top tier ... Consummate Provider™ solution in both the U.S. and ... SaaS based, Data Quality remediation portal, designed to ... party Providers improve their ability to capture, transmit ...
Breaking Biology Technology:Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... -- China-Biotics,Inc. (OTC Bulletin Board: CHBT) ("China-Biotics," "the ... research, development,marketing and distribution of probiotics products, today ... plant at Qing Pu, Shanghai., "The new ... the cornerstone of our,growth strategy. We have put ...
... drive solid ... earnings growth., ST. DAVID,S, Bermuda, May ... for the quarter ended,March 31, 2008. Revenue in the quarter ended March ... quarter. The primary,drivers of the increase in revenue were the net sales ...
... ... AI programs - ... TSX symbol: SBS, CALGARY, May 9 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), ... announced its,2008 first quarter operational and financial results., Highlights, - ...
Cached Biology Technology:China-Biotics, Inc. Completes Foundation for Its New Plant 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 3Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 4Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 5Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 6Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 7Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 8Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 9Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 10Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 11Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 12Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 13Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 14Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 15Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 16Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 17SemBioSys announces first quarter 2008 financial and operational results 2SemBioSys announces first quarter 2008 financial and operational results 3SemBioSys announces first quarter 2008 financial and operational results 4SemBioSys announces first quarter 2008 financial and operational results 5SemBioSys announces first quarter 2008 financial and operational results 6SemBioSys announces first quarter 2008 financial and operational results 7SemBioSys announces first quarter 2008 financial and operational results 8SemBioSys announces first quarter 2008 financial and operational results 9SemBioSys announces first quarter 2008 financial and operational results 10SemBioSys announces first quarter 2008 financial and operational results 11SemBioSys announces first quarter 2008 financial and operational results 12
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
(Date:11/2/2014)... ORLEANS, LA (2 November 2014)—In support of a bold ... Bill & Melinda Gates Foundation today announced an award ... Malaria Vaccine Initiative (MVI) in building new vaccines that ... help realize the "accelerating to zero" agenda. Such vaccines ... what could be called an "immunological bed net." ...
(Date:11/2/2014)... bar and bump into a biologist . . . , ... nerd sketch, researchers have taken this premise and applied it ... meaning in the rising oceans of genomic data. , In ... genome-wide studies are publishing at a dizzying rate. The challenge ... from the noise (and there is no shortage of noise). ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... spit out the bad. A new study from the Monell ... gatekeeper. The research shows that strong bitter taste in and ... of nausea and display a pattern of stomach activity characteristic ... of quality of life for many people, including pregnant women, ...
... booms, the science of making music, the impact of noise ... just some of the intriguing topics that will be presented ... (ASA). The meeting will take place May 23-27, ... The ASA offers complimentary press registration to bona fide working ...
... you don,t swallow it at allis enough to cause that ... according to a new study reported in the April 12th ... work shows that our body and our physiology anticipate the ... contain toxins or anti-nutrients," said Paul Breslin of the Monell ...
Cached Biology News:The nauseating taste of bitter 2The science of sound 2The science of sound 3The science of sound 4The science of sound 5The science of sound 6Bitterness induces nausea, swallowing not required 2
...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Donor Goat Serum...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Biology Products: